Lipocine's second quarter net loss widens to $2.6M as it plans a new trial for its PPD drug after a Phase 3 failure.

Lipocine reported a second quarter net loss of $2.6 million, or ($0.32) per share, compared to a net loss of $2.2 million, or ($0.41) per share, in the prior year. Total revenue declined to $0.19 million from $0.62 million, as royalty revenue growth was offset by the absence of license revenue recognized in the year-ago period. The company ended the quarter with $23.3 million in cash and marketable securities.

Key Highlights

• Total Q2 revenue fell to $0.19 million from $0.62 million year-over-year due to the lack of license revenue; however, royalty revenue from TLANDO sales grew 55% to $190,000.
• The company's lead drug candidate, LPCN 1154 for postpartum depression (PPD), failed to meet its primary endpoint in a Phase 3 trial. Lipocine is moving forward after a post hoc analysis suggested data anomalies at one trial site.
• Lipocine has initiated a new placebo-controlled clinical trial for LPCN 1154 and has an FDA guidance meeting scheduled for the third quarter of 2026 to discuss a potential development path.